COVID-19 Antibody and Reinfection Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4235 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-15

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to establish a cohort of Kaiser Permanente Colorado (KPCO) members who have and have not had COVID-19 infection for serial antibody testing and PCR testing to:

1. Quantify antibody titers among participants over 9 months.
2. Determine the rates of asymptomatic, mild, and severe recurrent infection among participants with prior COVID-19.
3. Examine association between antibody titer levels and risk of recurrent infection using a case control analysis nested in the cohort.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers

NCT04383587

SARS-CoV 2 COVID-19

COMPLETED NA

Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants

NCT05858502

COVID-19

RECRUITING NA

Neutralizing Antibody Level After COVID-19 Vaccination

NCT05083026

Covid19

UNKNOWN

Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19

NCT04543006

Covid19

UNKNOWN NA

Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays

NCT04562285

Covid19

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, the Kaiser Permanente Colorado (KPCO) Institute for Health Research (IHR) will evaluate SARS-CoV-2 IgG antibody titers over time among individuals with evidence of prior infection, and correlate antibody titers with risk of recurrent infection. The investigators will identify KPCO members who have and have not had prior infection, enroll them into a cohort study, conduct serial surveys for new COVID-19 symptoms, and facilitate serial viral and antibody testing.

All laboratory testing procedures and clinical management of participants will be conducted by KPCO operations. The research team will identify participants, obtain consent, administer surveys to assess COVID-19 symptoms, and direct patients to the appropriate testing. Health outcomes on cohort participants will be tracked with survey data on symptoms, clinical and utilization data from the KPCO electronic health record (e.g., hospitalization), and laboratory data (e.g., viral test results).

This research-operations partnership strategy will generate data to better understand the implications of positive antibody titers to this novel pathogen.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Testing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case

Case patients were drawn from a random sample of individuals who were enrolled in KPCO's health plan had suspected or confirmed SARS-CoV-2 infection and a random stratified sample of the general KPCO membership with similar age, gender, race/ethnicity and co-morbidities as case group. Within the cohort, case patients had a SARS-CoV-reinfection, defined as a positive SARS-CoV-2 RNA test ≥ 90 days after the first positive RNA test.

No interventions assigned to this group

Control

Control patients were drawn from a random sample of individuals who were enrolled in KPCO's health plan had suspected or confirmed SARS-CoV-2 infection and a random stratified sample of the general KPCO membership with similar age, gender, race/ethnicity and co-morbidities as case group. Within the cohort, control patients had no evidence of a SARS-CoV-reinfection during the period of interest.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion criteria are Kaiser Permanente Colorado health plan members, with a valid email address or phone number in the electronic health record and not on the Do Not Call List for research.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes